-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – ABBV-319 in Follicular Lymphoma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - ABBV-319 in Follicular Lymphoma report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. ABBV-319 in Follicular Lymphoma Drug Details: ABBV-319 is under development for the...
-
Product Insights
Cutaneous Mycosis – Drugs In Development, 2023
Global Markets Direct’s, ‘Cutaneous Mycosis - Drugs In Development, 2023’, provides an overview of the Cutaneous Mycosis pipeline landscape. The report provides comprehensive information on the therapeutics under development for Cutaneous Mycosis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an...
-
Product Insights
Acromegaly – Drugs In Development, 2023
Global Markets Direct’s, ‘Acromegaly - Drugs In Development, 2023’, provides an overview of the Acromegaly pipeline landscape. The report provides comprehensive information on the therapeutics under development for Acromegaly, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key...
-
Product Insights
Onychomycosis (Tinea Unguium) – Drugs In Development, 2023
Global Markets Direct’s, ‘Onychomycosis (Tinea Unguium) - Drugs In Development, 2023’, provides an overview of the Onychomycosis (Tinea Unguium) pipeline landscape. The report provides comprehensive information on the therapeutics under development for Onychomycosis (Tinea Unguium), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the...
-
Product Insights
Neuroendocrine Tumors – Drugs In Development, 2023
Global Markets Direct’s, ‘Neuroendocrine Tumors - Drugs In Development, 2023’, provides an overview of the Neuroendocrine Tumors pipeline landscape. The report provides comprehensive information on the therapeutics under development for Neuroendocrine Tumors, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an...
-
Product Insights
Mycoses – Drugs In Development, 2023
Global Markets Direct’s, ‘Mycoses - Drugs In Development, 2023’, provides an overview of the Mycoses pipeline landscape. The report provides comprehensive information on the therapeutics under development for Mycoses, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key...
-
Product Insights
Neuroendocrine Cancer – Drugs In Development, 2023
Global Markets Direct’s, ‘Neuroendocrine Cancer - Drugs In Development, 2023’, provides an overview of the Neuroendocrine Cancer pipeline landscape. The report provides comprehensive information on the therapeutics under development for Neuroendocrine Cancer, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – Octreotide acetate CR in Neuroendocrine Tumors
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Octreotide acetate CR in Neuroendocrine Tumors report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Octreotide acetate CR in Neuroendocrine Tumors Drug Details: Octreotide is...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Golimumab in Type 1 Diabetes (Juvenile Diabetes)
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalDatas proprietary machine learning algorithms developed using over 10 years of historical data.Golimumab in Type 1 Diabetes (Juvenile Diabetes) Drug Details:Golimumab (Simponi) is a human monoclonal antibody, acts...